This disclosure relates to treatments for reducing the side effects associated with treatment of a medication or drug, such as a chemotherapy medication, being experienced by a patient. This may be accomplished by administering to a patient taking the medication, a buffered aqueous liquid having a pH of about 10 to about 11.5, wherein the buffered aqueous liquid comprises sodium bicarbonate, sodium carbonate, and trisodium phosphate.

The present invention provides a pharmaceutical composition for removing drusen, suppressing formation of drusen, and/or treating and/or preventing age-related macular degeneration comprising the compound of formula (I) wherein Ra is independently selected from the group consisting of halo, hydroxy, alkyl, halo-substituted alkyl, aryl, halo- or alkyl-substituted aryl, alkoxy, hydroxy- or carboxy-substituted alkoxy, aryloxy, halo- or alkyl-substituted aryloxy, CHO, C(O)-alkyl, C(O)-aryl, C(O)-alkyl-carboxyl, C(O)-alkylene-carboxy ester and cyano, and m is an integer selected from 0 to 4.

The present invention provides a pharmaceutical composition for removing drusen, suppressing formation of drusen, and/or treating and/or preventing age-related macular degeneration comprising the compound of formula (I) wherein Ra is independently selected from the group consisting of halo, hydroxy, alkyl, halo-substituted alkyl, aryl, halo- or alkyl-substituted aryl, alkoxy, hydroxy- or carboxy-substituted alkoxy, aryloxy, halo- or alkyl-substituted aryloxy, CHO, C(O)-alkyl, C(O)-aryl, C(O)-alkyl-carboxyl, C(O)-alkylene-carboxy ester and cyano, and m is an integer selected from 0 to 4.

The present invention relates to methods of treating or preventing rheumatic disease.

The present invention relates to methods of treating or preventing rheumatic disease.

Methods, and kits for inducing cell death in proliferating cells as well as methods of treating cancer, are provided. In some embodiments, the methods comprise administering a composition comprising a replication competent retrovirus (RCR) comprising an antisense molecule that targets a hypoxia-inducible gene including but not limited to HIF-1 and CREB, and anti-cancer therapy.

Methods, and kits for inducing cell death in proliferating cells as well as methods of treating cancer, are provided. In some embodiments, the methods comprise administering a composition comprising a replication competent retrovirus (RCR) comprising an antisense molecule that targets a hypoxia-inducible gene including but not limited to HIF-1 and CREB, and anti-cancer therapy.

Methods, and kits for inducing cell death in proliferating cells as well as methods of treating cancer, are provided. In some embodiments, the methods comprise administering a composition comprising a replication competent retrovirus (RCR) comprising an antisense molecule that targets a hypoxia-inducible gene including but not limited to HIF-1 and CREB, and anti-cancer therapy.

A method for inducing a sustained immune response in humans or animal patient suffering from human immunodeficiency virus (HIV) acquired immune deficiency syndrome (AIDS, autoimmune disease, cancer, inflammation, and neurodegenerative diseases comprises daily administration to such patients a single oral tablet, rapidly dissolving film, capsule, liquid or cream dose of an Immediate release naltrexone composition comprising between about 0.01 to about 10 mg of naltrexone. In order to provide a benefit the naltrexone must be an Immediate release composition comprising between about 0.01 and about 10 mg of naltrexone

The present invention provides rebamipide for use in a method of prevention and/or treatment of Crohn's disease. In particular, rebamipide is used in prevention and/or treatment of Crohn's disease in a person suffering from increased intestinal permeability or in a person who is at risk of increased intestinal permeability.